Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access to ZofinTM (OrganicellTM Flow) for Patients With COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04657406
Expanded Access Status : Available
First Posted : December 8, 2020
Last Update Posted : January 5, 2021
Sponsor:
Collaborator:
bioRASI, LLC
Information provided by (Responsible Party):
Organicell Regenerative Medicine

Brief Summary:
This expanded access protocol will provide access to the investigational product ZofinTM (OrganicellTM Flow) for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider to be at high risk of progression to moderate disease.

Condition or disease Intervention/treatment
Covid19 Corona Virus Infection SARS (Severe Acute Respiratory Syndrome) Acute Respiratory Distress Syndrome Drug: ZofinTM

Detailed Description:

A human coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak worldwide. Common symptoms of COVID-19 include fever, cough, and shortness of breath. The majority of cases result in mild symptoms, but some can progress into pneumonia and multi-organ failure. According to the severity it is divided into mild, normal, severe and critically ill, which is associated with ICU admission and mortality. At present, the standard treatment of COVD-19 patients is oxygen therapy, mechanical ventilation, and medications to maintain blood pressure. As of today, no specific antiviral therapy is available for patients with COVID-19. Immune activation in some patients, and the appearance of cytokine storm syndrome (CSS) is one of the important causes of severe damage to lungs and other organs, which may lead to death. There is an urgent need to develop new interventions to suppress the excessive immune response in a timely manner during the course of disease, protect alveolar function, and reduce lung and systemic organ damage.

ZofinTM (OrganicellTM Flow) is an acellular, minimally manipulated product, derived from human amniotic fluid (HAF). This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from amniotic stem and epithelial cells. The product contains a mean concentration of 5.24x10^11 particles/mL with a mean mode size of 125.2nm. Surface marker analysis confirmed the presence of exosome associated proteins CD63, CD81, and CD9 in addition to high expression of CD133. The completed sequencing revealed 102 commonly expressed miRNA (with a 100-copy expression minimum). Bioinformatics analysis linked 63 miRNAs to 1216 RNA targets. Major players in the proinflammatory cytokine cascade found to be targeted by miRNA were discovered in Organicell's product include TNF, IL-6, and IL-8. Additionally, a broader array of pro-inflammatory cytokines is also targeted by the collection of miRNA such as FGF2, IFNB1, IGF1, IL36a, IL37, TGF-B2, VEGFA, CCL8, and CXCL12. It has been suggested in published research that inhibition or suppression of this pro-inflammatory cytokine cascade may reduce the severity of symptoms associated with elevated immune response. Furthermore, the miRNA was found to target 148 genes associated with immune response.

The property of ZofinTM (OrganicellTM Flow) demonstrates the therapeutic potential as a suppressor of cytokine activation for the reduction of COVID-19 infection severity. This is an open label expanded access protocol to treat subjects using ZofinTM (OrganicellTM Flow) for treatment of mild to moderate COVID-19 due to SARS-Cov-2.

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Treatment IND/Protocol
Official Title: Expanded Access to ZofinTM (OrganicellTM Flow) for the Treatment of Patients With Mild to Moderate COVID-19 Due to SARS-Cov-2 for Outpatient and Inpatient Population



Intervention Details:
  • Drug: ZofinTM
    Subjects will receive standard of care plus 1 mL of ZofinTM (OrganicellTM Flow) on day 0, day 4 and day 8, containing 1-5 x 1011 particles/mL.
    Other Name: OrganicellTM Flow

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  1. Provide written informed consent
  2. Subjects age > 18 years at the time of signing the Informed Consent Form.
  3. Male or Female
  4. Must have a clinical diagnosis of COVID-19 by the qualitative reverse-transcription polymerase chain reaction (RT-PCR), with at least one of mild or moderate COVID-19 clinical symptoms which are defined below in #5
  5. Individuals with mild to moderately COVID-19 symptoms for outpatient and inpatient population.

    The main symptoms of mild illness are:

    • low grade fever <38°C (37.5 to 37.9)
    • a dry cough
    • tiredness
    • feeling slightly breathless
    • muscle pain
    • headache
    • sore throat
    • diarrhea

    The main symptoms of moderate illness are:

    In addition to the symptoms patients may get with a mild illness, they may also experience:

    • fever ≥38°
    • a dry and more persistent cough several times an hour
    • tiredness and a need to stay in bed
    • feeling breathless when doing moderate exercise (such as walking upstairs)
    • muscle pain and aches and need to stay in bed
    • headache particularly if you are feeling hot
    • sore throat, soreness from coughing, but no pain
    • diarrhea
    • a dry mouth
  6. Adequate venous access
  7. For Women of Child-Bearing Potential (WOCBP) only, willingness to use FDA-recommended birth control until 6 months post treatment. The FDA-approved and cleared methods for birth control are listed below:

    • Permanent Sterilization
    • Long-Acting Reversible Contraceptives (LARC)
    • Contraceptive Injection
    • Short-Acting Hormonal Methods
    • Barrier Methods
    • Emergency Contraception

    https://www.fda.gov/consumers/free-publications-women/birth-control

  8. Any male subject must agree to use contraceptives and not donate sperm during the study.
  9. Must agree to comply with all protocol requirements and be willing to complete all study visits

Exclusion Criteria:

  1. Patients who have moderate to severe respiratory distress syndrome due to COVID-19
  2. Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female subjects must undergo a blood pregnancy test at screening which will be within 72 hours of the IP infusion.
  3. Inability to perform any of the assessments required.
  4. Active listing (or expected future listing) for transplant of any organ.
  5. Be a solid organ transplant recipient. This does not include prior cell-based therapy (>12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting. Have a history of organ or cell transplant rejection.
  6. History of drug abuse (illegal "street" drugs except marijuana (If it is legal use in states where patient resides), or prescription medications not being used appropriately for a pre-existing medical condition or alcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months
  7. Patients with untreated HIV infection. However, patients can be enrolled if have been treated for HIV and the test negative for HIV viral load but still test positive for antibodies.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04657406


Contacts
Layout table for location contacts
Contact: Mari Mitrani, MD, PhD 888-963-7881 clinicaltrials@organicell.com

Sponsors and Collaborators
Organicell Regenerative Medicine
bioRASI, LLC
Publications:
Cascella M, Rajnik M, Cuomo A, Dulebohn SC and Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19) StatPearls Treasure Island (FL); 2020
Center AM. Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19). 2020
Hospital B. Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection. 2020.
Hospital BY, Shenyang Tonglian Group Co. L, Medicine Io, Biotechnology CAoMS, Hospital HC, University SP, University FAHoCM, University TSAHoHM, City NPsHoF, College FAHBM, University RHoW, Shenyang Tspsho and Hospital NC. The Clinical Study of Carrimycin on Treatment Patients With COVID-19. 2020
Hospital T. A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia. 2020
Hospital T. A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia. 2020
Institut National de la Santé Et de la Recherche Médicale F. Trial of Treatments for COVID-19 in Hospitalized Adults. 2020
Kong TUoH and Hospital Authority HK. Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment. 2020
Ltd. JQPC. Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe). 2020
Ltd. JQPC. Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia. 2020
Nanchang TNHo and Ascletis Pharmaceuticals Co. L. Evaluation of Ganovo (Danoprevir ) Combined With Ritonavir in the Treatment of Novel Coronavirus Infection. 2020
University FAHoZ and Ascletis Pharmaceuticals Co. L. Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection. 2020
QU J and Hospital R. Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus. 2020
University SAHoWM and WanBangDe Pharmaceutical Group Co. L. Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19). 2020
Hospital PUF. Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019. 2020
Marche UPd and Nord AOORM. Tocilizumab for SARS-CoV2 Severe Pneumonitis. 2020.
Hospital T. A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia. 2020
Hospital T. Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients. 2020.
Peng Z, Ltd TBTC and Hospital Z. Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia. 2020
Allergy NIo and Diseases I. Adaptive COVID-19 Treatment Trial. 2020
Sciences G. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS- 5734™) in Participants With Severe Coronavirus Disease (COVID-19). 2020
Sciences G. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS- 5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment. 2020.
University CM. Severe 2019-nCoV Remdesivir RCT. 2020
University CM and Sciences CAoM. Mild/Moderate 2019-nCoV Remdesivir RCT. 2020
Center SPHC. Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV ). 2020
Minnesota Uo. Post-exposure Prophylaxis for SARS-Coronavirus-2. 2020.
National Institute of Respiratory Diseases M and Sanofi. Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial). 2020.
Hospital HPPs. Tetrandrine Tablets Used in the Treatment of COVID-19. 2020
Sciences CAoCM. Yinhu Qingwen Decoction for the Treatment of Mild Common CoVID-19. 2020.
Wang Z, Hospital WL, University TFAHoDM, Hospital TPs, Science NCUo, Hospital TA, Hospital JEFG and Sciences CAoCM. Yinhu Qingwen Granula for the Treatment of Severe CoVID-19. 2020.
Hospital MG, Hospital X and Fondazione IRCCS Ca' Granda OMP. Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19. 2020
Hospital MG, Hospital X, Fondazione IRCCS Ca' Granda OMP and Hospital N. Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19. 2020
Hospital X and Fondazione IRCCS Ca' Granda OMP. Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection. 2020.
Hospital X, Hospital MG and Fondazione IRCCS Ca' Granda OMP. Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19. 2020
NeuroRx I and SA RTH. Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress. 2020
OncoImmune I. CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment. 2020.
Wuhan Union Hospital C. Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients. 2020
Hospital T. The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19. 2020
Hospital PUMC, Tongji Hospital of Tongji Medical College HUoS and Technology. The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia. 2020.
Science PHAtWUo, Technology and Wuhan Hamilton Bio-technology Co. L. Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus. 2020
Hospital T-D. Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia. 2020
Southeast University C. Immunoregulatory Therapy for 2019-nCoV. 2020.
Pulmotect I. The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-CoV-2. 2020
Pulmotect I. The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID- 19 in Adults Positive for SARS-CoV-2 Infection. 2020
Pharmaceuticals R and Sanofi. Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19. 2020
Peng Z and Hospital Z. Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia. 2020.
University FAHoWM, University SAHoWM and Hospital WC. The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia. 2020
University FAHoWM, University SAHoWM and Hospital WC. The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19. 2020
University FAHoFM. Fingolimod in COVID-19. 2020
Hospital BCY. Efficacy and Safety of Corticosteroids in COVID-19. 2020
Hospital PUMC, Hospital Z, Hospital Z and University RHoW. Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure. 2020.
Hospital T. The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia. 2020.
Hospital B, CELL V, GENE ENGINEERING CORP. L, China, Wuhan Huoshenshan Hospital W, China, Hospital TH, Hospital STPs, Fifth Affiliated Hospital SY-SU, Wuhan Union Hospital C and Hospital WC. Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19). 2020
Hospital B, Innovative Precision Medicine Group H, China., Wuhan Huoshenshan Hospital W, China, Hospital TH, CELL V, GENE ENGINEERING CORP. L, China, Hospital STPs and Fifth Affiliated Hospital SY-SU. Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus. 2020.
CAR-T Biotechnology Co. L. Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells. 2020.
Wuhan Union Hospital C and Wuhan Hamilton Bio-technology Co. L, China. Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia. 2020.
Arabia SC. Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells. 2020.
Brasil A, Ltda CPC and Cruz HV. Mesenchymal Stem Cell NestCell® to Treat Patients With Severe COVID-19 Pneumonia. 2020
Inc. TSCB. Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2. 2020
University Xm and University FAHoXM. NK Cells Treatment for Novel Coronavirus Pneumonia. 2020
Tasly Pharmaceuticals I. The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19. 2020
Hospital T. A Pilot Study of Sildenafil in COVID-19. 2020.
Minnesota Uo. Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization. 2020.
Minnesota Uo. Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization. 2020.
Hospital S, Medicine HHoTC, Hospital JNPs and Hospital T. Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu. 2020
Cajal FplIBdHURy, III IdSC and pulmonar FdAalIslH. Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia in Preterm Babies. 2019
Hospital D, University tRIoSotTMM, University CsHoCM, Maternal C and Hospital CH. Stem Cells for Bronchopulmonary Dysplasia. 2017.
Ltd. MC. PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants. 2018
University CsHoCM. Follow-Up Study of Mesenchymal Stem Cells for Bronchopulmonary Dysplasia. 2018.
University CsHoCM. Human Mesenchymal Stem Cells For Infants At High Risk For Bronchopulmonary Dysplasia. 2019
Center MDAC and Foundation K. Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies. 2017
University SY-s. Human Umbilical Cord Mesenchymal Stem Cells (MSCs) Therapy in ARDS. 2018.
Clinic M. Mesenchymal Stem Cell Therapy for Lung Rejection. 2014
Clinic M. Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD). 2020.
Mesoblast I and Mesoblast L. PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). 2008.
Clinica Universidad de Navarra UdN. Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis. 2013
Dai J, Southwest Hospital C and Sciences CAo. A Study on Radiation-induced Pulmonary Fibrosis Treated With Clinical Grade Umbilical Cord Mesenchymal Stem Cells. 2014.
Hare JM, Lester T, Foundation SS, The Emmes Company L and Miami Uo. Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER). 2013.
Hospital TPC and Institute MMR. A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis. 2010.
Dai J, Southwest Hospital C, Hospital NC and Sciences CAo. A Study on Pneumoconiosis Treated With Whole-lung Lavage Combined With Mesenchymal Stem Cells. 2016.
Glassberg M and Miami Uo. Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis. 2016.
Glassberg M and Miami Uo. Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma. 2017
Hare JM and Miami Uo. Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis. 2020.
Roesch E, University CWR, Foundation CF and Center UHCM. Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis. 2016.
Hospital LPs. Clinical Study of Adipose Derived Mesenchymal Stem Cells for Treatment of Pulmonary Arterial Hypertension. 2019

Layout table for additonal information
Responsible Party: Organicell Regenerative Medicine
ClinicalTrials.gov Identifier: NCT04657406    
Other Study ID Numbers: 19881-EA
First Posted: December 8, 2020    Key Record Dates
Last Update Posted: January 5, 2021
Last Verified: December 2020
Keywords provided by Organicell Regenerative Medicine:
Human
Exosomes
Human Amniotic Fluid
Additional relevant MeSH terms:
Layout table for MeSH terms
Severe Acute Respiratory Syndrome
Coronavirus Infections
Respiratory Distress Syndrome, Newborn
Respiratory Distress Syndrome, Adult
Acute Lung Injury
Syndrome
Disease
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders
Infant, Premature, Diseases
Infant, Newborn, Diseases
Virus Diseases
Lung Injury
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Respiratory Tract Infections